Eysmann S B, Douglas P S
Harvard-Thorndike Laboratory, Beth Israel Hospital, Boston, MA 02215.
JAMA. 1992 Oct 14;268(14):1903-7.
One third of all deaths in women in the United States each year are attributable to coronary heart disease. Gender differences exist in the course and management of patients with coronary heart disease. Few randomized trials have been conducted in women to evaluate effective therapeutic strategies. With the aim of developing rational approaches to women with coronary heart disease, we review gender-related outcomes with coronary revascularization and reperfusion therapies.
English-language journal articles and reviews on the subject of women with coronary heart disease or gender-specific responses to coronary heart disease management, from 1970 through 1992, identified through MEDLINE searching.
Selected studies included only randomized controlled trials for topics related to thrombolysis, and articles considered to contribute significantly to the topic of women with coronary artery disease in the case of angioplasty and coronary artery bypass grafting.
Two reviewers participated in extracting the data with the aim of presenting a balanced and comprehensive review of the subject.
Thrombolysis in acute myocardial infarction reduces mortality in men and women, although women may have a reduced mortality benefit compared with men. Angioplasty and the newer interventional devices result in greater procedural morbidity but similar if not better long-term outcomes in women. Women may have a greater mortality rate than men with coronary artery bypass surgery, although studies suggest that outcome after bypass surgery may depend more on coronary size and preoperative risk factors than on gender itself.
The existence of gender differences in the course of coronary heart disease and response to revascularization and reperfusion strategies suggests the need for unique clinical approaches to the female patient with coronary heart disease and stresses the importance of developing randomized trials that enroll adequate numbers of women and that are designed to answer gender-specific questions.
在美国,每年有三分之一的女性死亡归因于冠心病。冠心病患者的病程及治疗存在性别差异。针对女性开展的评估有效治疗策略的随机试验较少。为了制定针对冠心病女性患者的合理治疗方法,我们回顾了与冠状动脉血运重建和再灌注治疗相关的性别差异结果。
通过医学在线数据库检索,获取了1970年至1992年期间关于冠心病女性患者或冠心病治疗中性别特异性反应的英文期刊文章及综述。
入选的研究仅包括与溶栓相关主题的随机对照试验,以及在血管成形术和冠状动脉搭桥手术中被认为对冠心病女性患者主题有重大贡献的文章。
两名审阅者参与数据提取,旨在对该主题进行全面且平衡的综述。
急性心肌梗死溶栓治疗可降低男性和女性的死亡率,不过与男性相比,女性的死亡率获益可能较低。血管成形术及新型介入设备会导致更高的手术并发症发生率,但在女性患者中,其长期效果即便不比男性更好,至少也是相似的。接受冠状动脉搭桥手术的女性死亡率可能高于男性,尽管研究表明,搭桥手术后的结果可能更多地取决于冠状动脉大小和术前风险因素,而非性别本身。
冠心病病程以及对血运重建和再灌注策略的反应存在性别差异,这表明需要针对冠心病女性患者采取独特的临床方法,并强调开展足够数量女性参与且旨在回答性别特异性问题的随机试验的重要性。